Cargando…

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

Malignant Pleural Mesothelioma (MPM) is a rare neoplasm that is typically diagnosed in a locally advanced stage, making it not eligible for radical surgery and requiring systemic treatment. Chemotherapy with platinum compounds and pemetrexed has been the only approved standard of care for approximat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borea, Federica, Franczak, Marika A., Garcia, Maria, Perrino, Matteo, Cordua, Nadia, Smolenski, Ryszard T., Peters, Godefridus J., Dziadziuszko, Rafal, Santoro, Armando, Zucali, Paolo A., Giovannetti, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253134/ https://www.ncbi.nlm.nih.gov/pubmed/37298116 http://dx.doi.org/10.3390/ijms24119165

Ejemplares similares

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer
por: Zucali, Paolo Andrea, et al.
Publicado: (2020)

Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma
por: Franczak, Marika A., et al.
Publicado: (2023)

Systemic treatments for thymic tumors: a narrative review
por: Zucali, Paolo Andrea, et al.
Publicado: (2021)

Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction
por: El Hassouni, Btissame, et al.
Publicado: (2020)

Correction: Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction
por: El Hassouni, Btissame, et al.
Publicado: (2021)

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
por: Dubois, Fatéméh, et al.
Publicado: (2022)

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
por: Li Petri, Giovanna, et al.
Publicado: (2020)

Prognostic and predictive role of [(18)F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
por: Zucali, Paolo Andrea, et al.
Publicado: (2017)

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
por: Pagano, Maria, et al.
Publicado: (2020)

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
por: Ceresoli, G L, et al.
Publicado: (2014)

Technicolour; oasis or mirage?
Publicado: (1981)

L'audio-mirage
por: Fenet, Joan
Publicado: (1973)

Technicolour - oasis or mirage?
por: Ellis, Jonathan Richard
Publicado: (1981)

Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma
por: Digifico, Elisabeth, et al.
Publicado: (2023)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
por: Rossini, Marika, et al.
Publicado: (2018)

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
por: Morani, Federica, et al.
Publicado: (2021)

Mirages of transition : the Peruvian altiplano, 1780-1930 /
por: Jacobsen, Nils, 1948-
Publicado: (1993)

Mirage of health : utopias, progress, and biological change /
por: Dubos, René J. 1901-1982 (René Jules)
Publicado: (1961)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Higgs Inflation as a Mirage
por: Espinosa, Jose Ramon
Publicado: (2015)

Technicolor : oasis ou mirage?
Publicado: (1981)

Maxillofacial Prosthesis: A Mirage
por: Hajira, Neha
Publicado: (2020)

Response—Liminality and the Mirage of Settlement
por: Hooker, Claire, et al.
Publicado: (2022)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment
por: Cugliari, Giovanni, et al.
Publicado: (2021)

Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets
por: Cavallari, Ilaria, et al.
Publicado: (2023)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
por: Canova, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0mls5dta2gfvlhi9f8i8thd2i4